XM does not provide services to residents of the United States of America.
Q
Q

QIEN

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Top of the Street: European telecoms, real estate, Qiagen, Ashtead

BUZZ-Top of the Street: European telecoms, real estate, Qiagen, Ashtead A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** J.P.Morgan expects the European property sector to get no help from lower yields in 2025, but still flags average 21% upside for the stocks: It cuts France's Gecina GFCP.PA to "neutral" from "overweight" due to its exposure to macro-political risks in France It cuts Belgian Cofinimmo COFB.BR to "underweight" from "neutral" on balance sh
A
B
C
G
J
M
Q
B

Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes

BUZZ-Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes ** Shares of Syros Pharmaceuticals SYRS.O down 24.1% at $0.20, trading at an all-time low ** Co terminates its partnership with QIAGEN Manchester Limited after a clinical trial for its blood cancer treatment, tamibarotene, failed to meet its main goal ** Implements reduction in workforce by about 94% ** In connection with the workforce reduction, CEO Conley Chee and CFO Jason Haas will be terminated with
Q

Qiagen NV reports results for the quarter ended in September 30 - Earnings Summary

Qiagen NV reports results for the quarter ended in September 30 - Earnings Summary Qiagen NV QGEN.N reported quarterly adjusted earnings of 57 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of 52 cents. The mean expectation of thirteen analysts for the quarter was for earnings of 54 cents per share.
Q

Qiagen NV <QGEN.N> expected to post earnings of 54 cents a share - Earnings Preview

Qiagen NV expected to post earnings of 54 cents a share - Earnings Preview Qiagen NV QGEN.N , QGEN.K is expected to show a rise in quarterly revenue when it reports results on November 6 for the period ending September 30 2024 The Venlo Limburg-based company is expected to report a 3.3% increase in revenue to $491.745 million from $475.89 million a year ago, according to the mean estimate from 11 analysts, based on LSEG data.
Q

Qiagen Receives FDA Clearance Of Qiastat-Dx Meningitis/Encephalitis Panel To Support Emergency Diagnostics

BRIEF-Qiagen Receives FDA Clearance Of Qiastat-Dx Meningitis/Encephalitis Panel To Support Emergency Diagnostics Nov 4 (Reuters) - QIAGEN NV QIA.DE : RECEIVES FDA CLEARANCE OF QIASTAT-DX MENINGITIS/ENCEPHALITIS PANEL TO SUPPORT EMERGENCY DIAGNOSTICS Source text: ID:nGNX4ZXmCD Further company coverage: QIA.DE (Gdansk Newsroom)
Q

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.